Article
Selinexor for the treatment of recurrent or metastatic salivary gland tumors: results from the GEMS-001 clinical trial.
2022-10-06
Abstract excerpt
<title>Abstract</title> <p>Background Salivary gland tumors (SGT) are rare with limited systemic treatments. We aimed to evaluate the activity of selinexor, an oral selective inhibitor of nuclear export, in patients with recurrent unresectable or metastatic SGT. Methods GEMS-001 is an open-label phase 2 study for patients with recurrent or metastatic SGT with two parts. In part 1 of the protocol, patients had t...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- be66cf4f-9e8e-566c-aa0b-1acabd485574
- DOI
- 10.21203/rs.3.rs-2114261/v1